Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | eng |
| dc.contributor.author | D’Marco, Luis | |
| dc.contributor.author | Guerra-Torres, Xavier | |
| dc.contributor.author | Viejo, Iris | |
| dc.contributor.author | Lopez-Romero, Luis | |
| dc.contributor.author | Yugueros, Alejandra | |
| dc.contributor.author | Bermúdez, Valmore | |
| dc.date.accessioned | 2023-09-04T14:38:54Z | |
| dc.date.available | 2023-09-04T14:38:54Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Diabetic kidney disease (DKD) is the leading cause of chronic and end-stage kidney disease worldwide. Its pathogenic mechanism is complex, and it can affect the entire structures of the kidneys such as the glomerulus, tubules and interstitium. Currently, the urinary albumin excretion rate and the estimated glomerular filtration rate are widely accepted as diagnostic criteria. However, some studies have reported a different or non-classical clinical course of DKD, with some patients showing declined kidney function with normal levels of albuminuria, known as the ‘non-albuminuric DKD’ phenotype. The pathogenesis of this phenotype remains unclear, but some clinical and pathological features have been postulated. This review explores the evidence regarding this topic. | eng |
| dc.format.mimetype | spa | |
| dc.identifier.doi | https://doi.org/10.17925/EE.2022.18.2.102 | |
| dc.identifier.issn | 27525457 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/13234 | |
| dc.language.iso | eng | eng |
| dc.publisher | Touch Medical Media | eng |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | eng |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | touchREVIEWS in Endocrinology | eng |
| dc.source | Vol. 18 No. 2 (2022) | |
| dc.subject | Diabetes | spa |
| dc.subject | Albuminuria | spa |
| dc.subject | Chronic kidney disease | eng |
| dc.subject | Cardiovascular disease | eng |
| dc.title | Non-albuminuric Diabetic Kidney Disease Phenotype: Beyond Albuminuria | eng |
| dc.type.driver | info:eu-repo/semantics/article | eng |
| dc.type.spa | Artículo científico | spa |
| dcterms.references | Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat Rev Nephrol.2016;12:73–81. | eng |
| dcterms.references | Reutens AT. Epidemiology of diabetic kidney disease.Med Clin North Am. 2013;97:1–18. | eng |
| dcterms.references | Doshi SM, Friedman AN. Diagnosis and management of type 2 diabetic kidney disease. Clin J Am Soc Nephrol. 2017;12:1366–73. | eng |
| dcterms.references | Laranjinha I, Matias P, Mateus S, et al. Diabetic kidney disease: Is there a non-albuminuric phenotype in type 2 diabetic patients? Nefrologia. 2016;36:503–9. | eng |
| dcterms.references | Korbut AI, Klimontov VV, Vinogradov IV, Romanov VV. Risk factors and urinary biomarkers of non-albuminuric and albuminuric chronic kidney disease in patients with type 2 diabetes. World J Diabetes. 2019;10:517–33. | eng |
| dcterms.references | Oshima M, Shimizu M, Yamanouchi M, et al. Trajectories of kidney function in diabetes: A clinicopathological update. Nat Rev Nephrol. 2021;17:740–50. | eng |
| dcterms.references | Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes. Diabetes. 2006;55:1832–9. | eng |
| dcterms.references | Pichaiwong W, Homsuwan W, Leelahavanichkul A. The prevalence of normoalbuminuria and renal impairment in type 2 diabetes mellitus. Clin Nephrol.2019;92:73–80. | eng |
| dcterms.references | Kopel J, Pena-Hernandez C, Nugent K. Evolving spectrum of diabetic nephropathy. World J Diabetes.2019;10:269–79. | eng |
| dcterms.references | Yamamoto Y, Hanai K, Mori T, et al. Kidney outcomes and all-cause mortality in people with type 2 diabetes exhibiting non-albuminuric kidney insufficiency. Diabetologia. 2022;65:234–45. | eng |
| dcterms.references | Penno G, Solini A, Orsi E, et al. Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study. Diabetologia. 2018;61:2277–89. | eng |
| dcterms.references | Kramer HJ. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273. | eng |
| dcterms.references | Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes. Diabetes. 2006;55:1832–9. | eng |
| dcterms.references | Yokoyama H, Sone H, Oishi M, et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: The Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant.2008;24:1212–9. | eng |
| dcterms.references | An JH, Cho YM, Yu HG, et al. The clinical characteristics of normoalbuminuric renal insufficiency in Korean type 2 diabetic patients: A possible early stage renal complication.J Korean Med Sci. 2009;24(Suppl. 1):S75. | eng |
| dcterms.references | Klimontov VV, Korbut AI. Albuminuric and non-albuminuric patterns of chronic kidney disease in type 2 diabetes. Diabetes Metab Syndr. 2019;13:474–9. | eng |
| dcterms.references | Jia X, Zang L, Pang P, et al. A study on the status of normoalbuminuric renal insufficiency among type 2 diabetes mellitus patients: A multicenter study based on a Chinese population.J Diabetes. 2022;14:15–25. | eng |
| dcterms.references | Shi S, Ni L, Gao L, Wu X. Comparison of nonalbuminuric and albuminuric diabetic kidney disease among patients with type 2 diabetes: A systematic review and meta-analysis. Front Endocrinol.2022;13:871272. | eng |
| dcterms.references | Viazzi F, Russo GT, Ceriello A, et al. Natural history and risk factors for diabetic kidney disease in patients with T2D: Lessons from the AMD-annals. J Nephrol.2019;32:517–25. | eng |
| dcterms.references | Fraser SDS, Roderick PJ, McIntyre NJ, et al. Assessment of proteinuria in patients with chronic kidney disease stage 3: Albuminuria and non-albumin proteinuria. PLoS One. 2014;9:e9826 | eng |
| dcterms.references | Warren B, Rebholz CM, Sang Y, et al. Diabetes and trajectories of estimated glomerular filtration rate: A prospective cohort analysis of the atherosclerosis risk in communities study. Diabetes Care. 2018;41:1646–53. | eng |
| dcterms.references | Krolewski AS, Niewczas MA, Skupien J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014;37:226–34. | eng |
| dcterms.references | Bermejo S, Pascual J, Soler MJ. The current role of renal biopsy in diabetic patients. Minerva Med. 2018;109:116–25. | eng |
| dcterms.references | Bermejo S, García-Carro C, Soler MJ. Diabetes and renal disease—should we biopsy? Nephrol Dial Transplant. 2021;36:1384–6. | eng |
| dcterms.references | Tong X, Yu Q, Ankawi G, et al. Insights into the role of renal biopsy in patients with T2DM: A literature review of global renal biopsy results. Diabetes Therapy. 2020;11:1983–99 | eng |
| dcterms.references | Gimenez-Civera E, Puchades Montesa MJ, Terrádez L, et al. Histological and clinical findings in adult autopsies of type 2 diabetes mellitus patients with or without diabetic kidney disease.Nephrol Dial Transplant. 2020;35(Suppl. 3). | eng |
| dcterms.references | Border WA, Yamamoto T, Noble NA. Transforming growth factor beta in diabetic nephropathy. Diabetes Metab Rev.1996;12:309–39. | eng |
| dcterms.references | Bader R, Bader H, Grund KE, et al. Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters. Pathol Res Pract.1980;167:204–16. | eng |
| dcterms.references | Lane PH, Steffes MW, Fioretto P, Mauer SM. Renal interstitial expansion in insulin-dependent diabetes mellitus.Kidney Int. 1993;43:661–7. | eng |
| dcterms.references | Taft JL, Nolan CJ, Yeung SP, et al. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes. 1994;43:1046–51. | eng |
| dcterms.references | Ekinci EI, Jerums G, Skene A, et al. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care. 2013;36:3620–6. | eng |
| dcterms.references | Bhalla V, Zhao B, Azar KMJ, et al. Racial/ethnic differences in the prevalence of proteinuric and nonproteinuric diabetic kidney disease. Diabetes Care. 2013;36:1215–21. | eng |
| dcterms.references | Kume S, Araki S, Ugi S, et al. Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014. J Diabetes Investig. 2019;10:1032–40. | eng |
| dcterms.references | Bash LD, Selvin E, Steffes M, et al. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy. Arch Intern Med.2008;168:2440. | eng |
| dcterms.references | Bae J, Won YJ, Lee BW. Non-albumin proteinuria (NAP) as a complementary marker for diabetic kidney disease (DKD). Life. 2021;11:224. | eng |
| dcterms.references | Papadopoulou-Marketou N, Kanaka-Gantenbein C, Marketos N, et al. Biomarkers of diabetic nephropathy: A 2017 update. Crit Rev Clin Lab Sci.2017;54:326–42. | eng |
| dcterms.references | Wei T, Zhao L, Jia J, et al. Metabonomic analysis of potential biomarkers and drug targets involved in diabetic nephropathy mice. Sci Rep. 2015;5:11998. | eng |
| dcterms.references | Zürbig P, Jerums G, Hovind P, et al. Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes. 2012;61:3304–13. | eng |
| dcterms.references | Leoncini G, Viazzi F, de Cosmo S, et al. Blood pressure reduction and RAAS inhibition in diabetic kidney disease: Therapeutic potentials and limitations.J Nephrol. 2020;33:949–63. | eng |
| dcterms.references | de Boer IH, Caramori ML, Chan JCN, et al. KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98:S1–S115. | eng |
| dcterms.references | Chaturvedi N. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787–92. | eng |
| dcterms.references | Ravid M. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med. 1998;128:982. | eng |
| dcterms.references | Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med.2019;380:347–57. | eng |
| dcterms.references | Mosenzon O, Wiviott SD, Heerspink HJL, et al. The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58. Diabetes Care. 2021;44:1805–15. | eng |
| dcterms.references | Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med.2017;377:644–57. | eng |
| dcterms.references | Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. | eng |
| dcterms.references | Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: Effects in acute and chronic kidney disease. Curr Diab Rep. 2022;22:39–52. | eng |
| dcterms.references | Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med.2016;375:323–34. | eng |
| dcterms.references | Górriz JL, Soler MJ, Navarro-González JF, et al. GLP-1 receptor agonists and diabetic kidney disease: A call of attention to nephrologists.J Clin Med. 2020;9:947. | eng |
| dcterms.references | Lerma E, White WB, Bakris G. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. Postgrad Med. 2022:1–10. | eng |
| dcterms.references | D’Marco L, Puchades MJ, Gandía L, et al. Finerenone: A potential treatment for patients with chronic kidney disease and type 2 diabetes mellitus. Eur Endocrinol. 2021;17:84. | eng |
| dcterms.references | Williams DM, Evans M. Semaglutide: Charting new horizons in GLP-1 analogue outcome studies. Diabetes Ther. 2020;11:2221–35. | eng |
| dcterms.references | Rodríguez-Morán M, González-González G, Bermúdez-Barba MV, et al. Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria; A double-blind, placebo-controlled randomized trial. Clin Nephrol.2006;66:3–10. | eng |
| dcterms.references | Leehey DJ. Targeting inflammation in diabetic kidney disease: Is there a role for pentoxifylline? Kidney360. 2020;1:292–9. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion | eng |